{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T02:26:07Z","timestamp":1794363967651,"version":"4.9.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Psoriasis is a common, chronic, inflammatory, debilitating, systemic disease with a great impact on healthcare systems worldwide. As targeted therapies have transformed the therapeutic landscape, updated estimates of the Global Burden of Disease (GBD) imposed by psoriasis are necessary in order to evaluate the effects of past health care policies and to orient and inform new national and international healthcare strategies.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Data were extracted from the GBD 2019 study, which collates a systematic review of relevant scientific literature, national surveys, claims data, and primary care sources on the prevalence of psoriasis. Prevalence data were combined with disability weight (DW) to yield years lived with disability (YLDs). Measures of burden at global, regional, and national levels were generated for incidence, prevalence, and YLDs, due to psoriatic disease. All measures were reported as absolute numbers, percentages, and crude and age-adjusted rates per 100,000 persons. In addition, psoriasis burden was assessed by socio-demographic index (SDI).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Findings:<\/jats:bold>\n                    According to the GBD 2019 methodology, there were 4,622,594 (95% uncertainty interval or UI 4,458,904\u20134,780,771) incident cases of psoriasis worldwide in 2019. The age-standardized incidence rate in 2019 was 57.8 (95% UI 55.8\u201359.7) per 100,000 people. With respect to 1990, this corresponded to a decrease of 20.0% (95% UI \u221220.2 to \u221219.8). By sex, the age-standardized incidence rate was similar between men [57.8 (95% UI 55.8\u201359.8) per 100,000 people] and women [(57.8 (95% UI 55.8\u201359.7) per 100,000 people]. With respect to 1990, this corresponded to a decrease by 19.5% (95% UI \u221219.8 to \u221219.2) and by 20.4% (95% UI \u221220.7 to \u221220.2) for men and women, respectively. The age-standardized incidence rate per 100,000 persons was found to vary widely across geographic locations. Regionally, high-income countries and territories had the highest age-standardized incidence rate of psoriasis [112.6 (95% UI 108.9\u2013116.1)], followed by high-middle SDI countries [69.4 (95% UI 67.1\u201371.9)], while low SDI countries reported the lowest rate [38.1 (95% UI 36.8\u201339.5)]. Similar trends were detected for prevalence and YLDs.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    In general, psoriasis burden is greatest in the age group of 60\u201369 years, with a relatively similar burden among men and women. The burden is disproportionately greater in high-income and high SDI index countries of North America and Europe. With advances in psoriasis therapeutics, objective evaluation of psoriasis disease burden is critical to track the progress at the population level.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2021.743180","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T05:22:50Z","timestamp":1639632170000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":367,"title":["The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study"],"prefix":"10.3389","volume":"8","author":[{"given":"Giovanni","family":"Damiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Luigi","family":"Bragazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chante","family":"Karimkhani Aksut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongze","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Alicandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dellavalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Grada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"La Vecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai-Shan","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Naghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41584-018-0147-9","article-title":"Pathophysiology, assessment and treatment of psoriatic dactylitis","volume":"15","author":"McGonagle","year":"2019","journal-title":"Nat Rev Rheumatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: from pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat Rev Rheumatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/PTT.S126281","article-title":"Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management","volume":"7","author":"Haneke","year":"2017","journal-title":"Psoriasis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Identification and management of psoriasis and associated comorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1136\/annrheumdis-2018-214065","article-title":"Prevalence and incidence of psoriasis and psoriatic arthritis","volume":"78","author":"Sewerin","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e028116","DOI":"10.1136\/bmjopen-2018-028116","article-title":"Prevalence and characteristics of psoriasis in Denmark: findings from the Danish skin cohort","volume":"9","author":"Egeberg","year":"2019","journal-title":"BMJ Open."},{"key":"B8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00296-013-2876-z","article-title":"High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study","volume":"34","author":"Henes","year":"2014","journal-title":"Rheumatol Int."},{"key":"B9","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2012-201706","article-title":"High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimalperformance of screening questionnaires","volume":"72","author":"Haroon","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/art.40830","article-title":"Identification of novel autoantibodies associated with psoriatic arthritis","volume":"71","author":"Yuan","year":"2019","journal-title":"Art Rheumatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis","volume":"5","author":"Lande","year":"2014","journal-title":"Nat Commun."},{"key":"B12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.5114\/aoms.2018.74021","article-title":"Serum lipid metabolism in psoriasis and psoriatic arthritis - an update","volume":"15","author":"Pietrzak","year":"2019","journal-title":"Arch Med Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/jdv.14460","article-title":"Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression","volume":"31","author":"Koo","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1159\/000450826","article-title":"Systematic review of health-related quality of life in adolescents with psoriasis","volume":"232","author":"Gonzalez","year":"2016","journal-title":"Dermatology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jaad.2017.10.012","article-title":"Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the corrona psoriasis registry","volume":"78","author":"Strober","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"396","year":"2020","journal-title":"Lancet."},{"key":"B17","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(12)61899-6","article-title":"GBD 2010: design, definitions, and metrics","volume":"380","author":"Murray","year":"2012","journal-title":"Lancet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61690-0","article-title":"Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010","volume":"380","author":"Murray","year":"2012","journal-title":"Lancet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1016\/S0140-6736(15)61340-X","article-title":"Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition","volume":"386","author":"GBD 2013 DALYs HALE","year":"2015","journal-title":"Lancet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/S0140-6736(17)32130-X","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016","volume":"390","author":"GBD 2016 DALYs HALE","year":"2017","journal-title":"Lancet."},{"key":"B22","volume-title":"Global Burden of Disease Study 2017 (GBD 2017) Disability Weights","year":"2018"},{"key":"B23","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1001\/jamadermatol.2016.5538","article-title":"Global skin disease morbidity and mortality: an update from the global burden of disease study 2013","volume":"23","author":"Karimkhani","year":"2017","journal-title":"JAMA Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1016\/S0140-6736(16)31467-2","article-title":"Measuring the health-related sustainable development goals in 188 countries: a baseline analysis from the global burden of disease study 2015","volume":"388","author":"GBD","year":"2016","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/S0140-6736(16)30388-9","article-title":"Guidelines for accurate and transparent health estimates reporting: the GATHER statement","volume":"388","author":"Stevens","year":"2016","journal-title":"Lancet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s10875-017-0464-9","article-title":"International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity","volume":"38","author":"Picard","year":"2018","journal-title":"J Clin Immunol."},{"key":"B27","unstructured":"Consanguinity around the world: what do the genomic data of the HGDP-CEPH diversity panel tell us?5837\n            LeuteneggerA\n            SahbatouM\n            GazalS\n            CannH\n            GeninE\n          10.1038\/ejhg.2010.20521364699Eur J Hum Genet.192011"},{"key":"B28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40257-017-0332-7","article-title":"Psoriasis in skin of color: insights into the epidemiology, clinical presentation, genetics, quality-of-life impact, and treatment of psoriasis in non-white racial\/ethnic groups","volume":"19","author":"Kaufman","year":"2018","journal-title":"Am J Clin Dermatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/ijd.14864","article-title":"Global burden of psoriasis - comparison of regional and global epidemiology, 1990 to 2017","volume":"59","author":"AlQassimi","year":"2020","journal-title":"Int J Dermatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.04.139","article-title":"The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: A systematic analysis from the global burden of disease study 2017","volume":"84","author":"Mehrmal","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"B32","doi-asserted-by":"publisher","first-page":"472","DOI":"10.46234\/ccdcw2021.123","article-title":"Burden of skin disease - China, 1990-2019","volume":"3","author":"Peng","year":"2021","journal-title":"China CDC Wkly."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e554","DOI":"10.1111\/ajd.13710","article-title":"Demographic and epidemiological drivers of global burden of psoriasis","volume":"62","author":"Xu","year":"2021","journal-title":"Australas J Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","article-title":"The psychosocial burden of psoriatic arthritis","volume":"47","author":"Husni","year":"2017","journal-title":"Semin Arthritis Rheum."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.jaad.2018.12.037","article-title":"All-cause and cause-specific mortality in psoriasis: a systematic review and meta-analysis","volume":"80","author":"Dhana","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","article-title":"Psoriasis severity and the prevalence of major medical comorbidity: a population-based study","volume":"149","author":"Yeung","year":"2013","journal-title":"JAMA Dermatol."},{"key":"B37","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/S0140-6736(18)32281-5","article-title":"Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related sustainable development goals for 195 countries and territories: a systematic analysis for the global burden of disease study 2017","volume":"392","author":"GBD","year":"2018","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","article-title":"British association of dermatologists' guidelines for biologic interventions for psoriasis 2009","volume":"161","author":"Smith","year":"2009","journal-title":"Br J Dermatol."},{"key":"B39","unstructured":"AnandA\n          Psoriasis Treatment Market Size Worth US $10.68 Billion by 20222019"},{"key":"B40","first-page":"ii65","article-title":"Psoriasis assessment tools in clinical trials","volume-title":"Ann Rheum Dis.","author":"Feldman","year":"2005"},{"key":"B41","unstructured":"Protocol for the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD)2018"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.743180\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T05:23:00Z","timestamp":1639632180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.743180\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,16]]},"references-count":41,"alternative-id":["10.3389\/fmed.2021.743180"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.743180","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fmed.2021.743180.s001","asserted-by":"subject"}]},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,16]]},"article-number":"743180"}}